EPHA2 and cancer: A variety of EphA2-targeting strategies, including peptide–drug conjugates, liposomal siRNA, chimeric antigen receptor (CAR)-T cells, and dendritic cell (DC) vaccines, are currently being tested in various cancer clinical trials around the world (NCT05631886, NCT01591356, NCT05631899, NCT06972576, NCT06710158, NCT04180371, NCT05283109, NCT06186401).